ImmuCell Basic EPS 2010-2024 | ICCC
ImmuCell basic eps from 2010 to 2024. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
| ImmuCell Annual Basic EPS | |
|---|---|
| 2024 | $-0.26 |
| 2023 | $-0.75 |
| 2022 | $-0.32 |
| 2021 | $-0.01 |
| 2020 | $-0.14 |
| 2019 | $-0.19 |
| 2018 | $-0.42 |
| 2017 | $-0.03 |
| 2016 | $0.12 |
| 2015 | $0.40 |
| 2014 | $-0.06 |
| 2013 | $0.04 |
| 2012 | $0.03 |
| 2011 | $-0.14 |
| 2010 | $-0.13 |
| 2009 | $-0.07 |
| ImmuCell Quarterly Basic EPS | |
|---|---|
| 2024-12-31 | $0.09 |
| 2024-09-30 | $-0.09 |
| 2024-06-30 | $-0.20 |
| 2024-03-31 | $-0.06 |
| 2023-12-31 | $-0.15 |
| 2023-09-30 | $-0.12 |
| 2023-06-30 | $-0.18 |
| 2023-03-31 | $-0.30 |
| 2022-12-31 | $-0.22 |
| 2022-09-30 | $-0.08 |
| 2022-06-30 | $-0.09 |
| 2022-03-31 | $0.07 |
| 2021-12-31 | $0.01 |
| 2021-09-30 | $0.02 |
| 2021-06-30 | $0.02 |
| 2021-03-31 | $-0.06 |
| 2020-12-31 | $0.03 |
| 2020-09-30 | $-0.04 |
| 2020-06-30 | $-0.11 |
| 2020-03-31 | $-0.02 |
| 2019-12-31 | $-0.06 |
| 2019-09-30 | $-0.07 |
| 2019-06-30 | $-0.09 |
| 2019-03-31 | $0.03 |
| 2018-12-31 | $-0.18 |
| 2018-09-30 | $-0.05 |
| 2018-06-30 | $-0.15 |
| 2018-03-31 | $-0.04 |
| 2017-12-31 | $-0.03 |
| 2017-09-30 | $-0.07 |
| 2017-06-30 | $-0.05 |
| 2017-03-31 | $0.12 |
| 2016-12-31 | $-0.01 |
| 2016-09-30 | $0.01 |
| 2016-06-30 | $0.00 |
| 2016-03-31 | $0.12 |
| 2015-12-31 | $0.09 |
| 2015-09-30 | $0.12 |
| 2015-06-30 | $0.03 |
| 2015-03-31 | $0.16 |
| 2014-12-31 | $0.04 |
| 2014-09-30 | $0.00 |
| 2014-06-30 | $-0.10 |
| 2014-03-31 | $0.00 |
| 2013-12-31 | $-0.05 |
| 2013-09-30 | $0.02 |
| 2013-06-30 | $0.00 |
| 2013-03-31 | $0.07 |
| 2012-12-31 | $-0.01 |
| 2012-09-30 | $-0.02 |
| 2012-06-30 | $0.01 |
| 2012-03-31 | $0.05 |
| 2011-12-31 | |
| 2011-09-30 | $-0.04 |
| 2011-06-30 | $-0.09 |
| 2011-03-31 | $-0.01 |
| 2010-12-31 | $0.04 |
| 2010-09-30 | $-0.07 |
| 2010-06-30 | $0.00 |
| 2010-03-31 | $-0.02 |
| 2009-12-31 | $-0.01 |
| 2009-09-30 | $-0.01 |
| 2009-06-30 | $-0.05 |
| 2009-03-31 | $-0.01 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.048B | $0.026B |
| ImmuCell Corp. is a biotechnology company striving to build shareholder value by commercializing proprietary technologies and helping dairy and beef producers and their veterinarians manage disease and reproduction in their herds. The company is also conducting an open label, efficacy study of DiffGAM, a human application of its milk-derived passive antibodytechnology for use as an alternative to antibiotics in the treatment and/or prevention of Clostridium difficile-associated diarrhea. | |||